Office: South San Francisco, CA

Robert DeBenedetto, CPA
Venture Partner

Robert DeBenedetto joins Clarus with over 25 years of global pharmaceutical and life sciences experience, including the management of approximately 100 acquisitions, mergers, licensing and partnering arrangements valued at over $10 billion. He is currently CEO of SFJ Pharmaceuticals, which he founded in January 2009. Prior to founding SFJ, Mr. DeBenedetto was Vice President of Global Business Development at Quintiles Pharmaceuticals investment unit and served as Executive Committee Member, Chief Financial Officer, Vice President of Corporate Development, and Vice President of Corporate Marketing for Boston Scientific’s Japan subsidiary. Mr. DeBenedetto started his professional career as a CPA with Ernest &Young, where he advised some of the world’s largest companies. He earned an MBA from Bentley University and an undergraduate degree in finance and accounting from Northeastern University. The SFJ Pharmaceuticals Group is a global Pharmaceutical company with an innovative business model that provides a financially advantageous and creative approach to drug development. SFJ’s unique partnering model pairs strategic funding and experienced clinical development resources with late phase drug development candidates across multiple indications. The result is accelerated portfolio expansion with minimal financial risk. SFJ Pharmaceuticals Group is staffed with a seasoned team of professionals, with extensive experience in the clinical development and regulatory approval of pharmaceutical products on a global basis. SFJ Pharmaceuticals Group has offices in the United States, Japan, Singapore, Korea, China, Spain and Germany.

Clarus Board Seats